





RACE  
ONCOLOGY

ASX: RAC



# H1 FY25 Report

Financial statements for the half year ended  
31 December 2024

At the **heart** of cancer care

For personal use only

**Race Oncology Limited**  
**Appendix 4D**  
**Half-year report**

**1. Company details**

Name of entity: Race Oncology Limited  
ABN: 61149318749  
Reporting period: For the half-year ended 31 December 2024  
Previous period: For the half-year ended 31 December 2023

**2. Results for announcement to the market**

	31 Dec 2024	31 Dec 2023	Change	Change
	\$	\$	\$	%
Profit/(loss) from ordinary activities after tax attributable to the owners of Race Oncology Limited	502,163	(5,663,158)	6,165,321	(109%)
Profit/(loss) for the half-year attributable to the owners of Race Oncology Limited	502,163	(5,663,158)	6,165,321	(109%)

*Dividends*

There were no dividends paid, recommended or declared during the current financial period.

*Comments*

The profit for the consolidated entity after providing for income tax amounted to \$502,163 (31 December 2023: loss of \$5,663,158).

**3. Net tangible assets**

	31 Dec 2024 Cents	31 Dec 2023 Cents
Net tangible assets per ordinary security	<u>10.39</u>	<u>10.77</u>

**4. Control gained over entities**

Not applicable.

**5. Loss of control over entities**

Not applicable.

**6. Dividends**

*Current period*

There were no dividends paid, recommended or declared during the current financial period.

*Previous period*

There were no dividends paid, recommended or declared during the previous financial period.

**7. Dividend reinvestment plans**

Not applicable.

**8. Details of associates and joint venture entities**

Not applicable.

---

**9. Foreign entities**

On 6 October 2017, the Company incorporated a subsidiary in Belgium, Race Oncology Belgium (Company Number 0682664917). There have been no significant financial transactions through the subsidiary at 31 December 2024.

---

**10. Audit qualification or review**

This report has been based on accounts that have been subject to an auditor's review. There are no items of dispute with the auditor and the review is not subject to qualification.

---

**11. Attachments**

*Details of attachments (if any):*

The Interim Report of Race Oncology Limited for the half-year ended 31 December 2024 is attached.

---

**12. Signed**

Signed *Daniel Tillett*

Date: 25 February 2025

Daniel Tillett  
Managing Director

Approved by the Board of Race Oncology Limited

**Race Oncology Limited**

**ABN 61149318749**

**Interim Report for the half year ended - 31 December 2024**

For personal use only

**Race Oncology Limited**  
**Directors' Report**  
**For the half-year ended 31 December 2024**

**Contents**

Directors' Report	2
Auditor's Independence Declaration	6
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income	7
Condensed Consolidated Statement of Financial Position	8
Condensed Consolidated Statement of Changes in Equity	9
Condensed Consolidated Statement of Cash Flows	10
Notes to the Condensed Consolidated Financial Statements	11
Directors' Declaration	15
Independent Auditor's Review Report	16

**General information**

The financial statements cover Race Oncology Limited as a consolidated entity consisting of Race Oncology Limited and the entities it controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars, which is Race Oncology Limited's functional and presentation currency.

Race Oncology Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

Race Oncology Limited  
Level 36 Gateway 1 Macquarie Place  
Sydney, NSW 2000  
Ph: +61 2 8051 3043  
Website: [www.raceoncology.com](http://www.raceoncology.com)

A description of the nature of the consolidated entity's operations and its principal activities is included in the Directors' Report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of the Directors, on 25 February 2025.

**Race Oncology Limited**  
**Directors' Report**  
**For the half-year ended 31 December 2024**

The Directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity') consisting of Race Oncology Limited (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 31 December 2024.

**Directors**

Your Directors present the financial report of the Company for the half year ended 31 December 2024.

**Directors**

The names and the particulars of the Directors of the Company during the half year and to the date of this report are:

<b>Name</b>	<b>Status</b>	<b>Appointed</b>
<b>Board</b>		
Megan Baldwin	Non-Executive Director (Independent)	1 January 2025
Sergio Scrofani	Non-Executive Director (Independent)	1 September 2024
Mary Harney	Non-Executive Chair (Independent)	8 February 2021 (Resigned 1 September 2024)
Phillip Lynch	Non-Executive Director (Independent)	1 June 2020 (Resigned 1 September 2024)
<b>Board and Executive</b>		
Peter Smith	Executive Director / Chair	28 June 2023 (Appointed Chair 1 September 2024)
Daniel Tillett	Chief Executive Officer and Managing Director	22 November 2023 (Appointed Managing Director 1 September 2024)
<b>Company Secretary</b>		
Peter Webse		

**Race Oncology Limited**  
**Directors' Report**  
**For the half-year ended 31 December 2024**

## **Operations**

On 2 July 2024, Race announced the appointment of Professor Daniel Von Hoff to Race's Clinical Advisory Board. Prof. Daniel D. Von Hoff, M.D., F.A.C.P. FASCO, FAACR is an eminent physician and is the Executive Vice President of the Molecular Medicine Division and Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona and City of Hope Cancer Center. Professor Von Hoff is a pioneering world leader in translational medicine, accelerating novel drug discoveries from the laboratory to cancer treatments in clinical trials, where he has been involved in over 300 clinical studies. His major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. Early in his career, Prof. Von Hoff worked with the original developers of bisantrene, Lederle Laboratories, in the design and execution of the bisantrene clinical studies. He has authored more than 10 publications on bisantrene.

On 12 July 2024, Dr Daniel Tillett & Dr Pete Smith met with shareholders and provided an investor update in Fremantle, Western Australia. The meeting was attended by more than 60 shareholders and interested investors. The shareholder meeting coincided with Race's presentation and investor and broker meetings at the 18<sup>th</sup> Bioshares Biotech Summit.

On 30 July 2024, Race announced that the investigator-sponsored Phase 1b/2 trial of bisantrene in combination with clofarabine and fludarabine (Bis/Clo/Flu) in relapsed or refractory acute myeloid leukaemia (R/R AML) patients had been successfully concluded, having achieved its primary endpoint for efficacy. The trial (NCT04989335) was conducted at the Chaim Sheba Medical Centre in Israel under the supervision of AML key opinion leader Professor Arnon Nagler. As previously disclosed (ASX Announcement: 6 November 2023), six of the 15 evaluable patients (40%) in the Phase 2 efficacy stage responded to the Bis/Clo/Flu treatment (five complete responses, one partial response), with three of the clinical responders having active extramedullary disease. Five of the six treatment-responsive patients were able to be bridged to a potentially curative stem cell transplant within one to three months of treatment.

On 30 & 31 July 2024, Race's Dr Daniel Tillett & Dr Pete Smith presented at the TechKnow Invest Roadshow on 30 July 2024 in Sydney and 31 July 2024 in Melbourne. Drs Smith & Tillett discussed Race's RC220 bisantrene program and upcoming milestones, as well as cancer survivorship and the importance of cardioprotection in cancer treatment.

On 2 September 2024, Race announced a Board renewal with the retirement of Ms Mary Harney from the Board after nearly four years, initially in the role of Non-Executive Director and as Non-Executive Chair since April 2023. Mr Phil Lynch retired from the Board, after a period of four years with Race, through which time he had served as both a Non-Executive Director and Chief Executive Officer/Managing Director. As part of the renewal, Dr Pete Smith was appointed Executive Chair and Dr Daniel Tillett moved from Chief Executive Officer to Chief Executive Officer/Managing Director. Dr Serge Scrofani was appointed as an Independent Non-Executive Director. Dr Serge Scrofani has more than 28 years' experience in the healthcare sector, working in global roles across research, strategy and corporate development. He served as Vice President of Strategy & Corporate Development at CSL for 13 years where he played a pivotal role in multiple strategic initiatives. Prior to this, he led Business Development for CSL Behring based in the US.

On 2 September 2024, Race received a positive determination from AusIndustry regarding eligibility of overseas R&D activities and was issued an R&D Tax Incentive Advance and Overseas Finding Assessment for \$20,081,627 over three years. This advanced finding assessment is a binding, underwritten guarantee, provided by the Australian Government which affirms that Race's R&D activities are of national interest and extends the 48.5% R&D rebate to eligible R&D activities up to \$20.1m undertaken outside of Australia between 1 July 2023 to 30 June 2026.

On 26 September 2024, Race presented at the at the E&P Small Cap Healthcare Conference in Sydney where Drs Smith & Tillett provided an overview of Race's lead oncology drug, RC220 bisantrene, an update on development progress, and the latest clinical plans, to sophisticated and institutional investors.

On 4 October 2024, Race submitted a provisional patent application for the RC220 bisantrene formulation. This patent, if granted, would provide exclusive IP protection of the RC220 formulation until October 2044.

On 21 November 2024, Race announced the discovery of 39 unique FTO protein-binding molecules identified using state-of-the-art NMR fragment screening. The identified compounds are confirmed FTO-binding chemical structures for the development of novel FTO targeting drugs and provide valuable new IP, aiding the development of novel m<sup>6</sup>A RNA epigenetic pathway drugs. This FTO-targeted drug discovery program was completed in collaboration with the Monash University Fragment Platform (MFP).

**Race Oncology Limited**  
**Directors' Report**  
**For the half-year ended 31 December 2024**

On 5 December 2024, Race announced submission of the ethics and regulatory package to Bellberry Human Research Ethics Committee (HREC) for approval of a Phase 1 clinical trial of RC220 at the Australian lead site, Southside Cancer Care Centre (Miranda, NSW). Following approval, this site will be activated for patient recruitment and institutional approval, with first patient recruitment anticipated in Q1 2025. In parallel, regulatory and institutional packages have been completed for submission to a second Australian site, immediately following HREC approval of the trial, with both sites planned to be activated simultaneously. Regulatory and institutional packages are in advanced preparation for multiple locations in Hong Kong and South Korea, with submissions anticipated in Q1 2025. Additional site evaluation and recruitment is ongoing with the aim of achieving 10 sites running the RC220 Phase 1 clinical trial.

On 17 December 2024, Race announced that it had received \$5,254,557 via the Research & Development (R&D) Tax Incentive from the Australian Taxation Office (ATO) for the financial year ended 30 June 2024 (FY2024).

On 18 December 2024, Race announced the appointment of experienced biotechnology executive, Dr Megan Baldwin, to its board as an Independent Non-Executive Director, effective 1 January 2025. Dr Baldwin is the Founder and Chief Innovation Officer of Opthea Limited (ASX:OPT; NASDAQ:OPT), a late-stage biopharmaceutical company, developing a novel therapy to address the unmet need in the treatment of retinal eye diseases. Her experience includes 10 years as CEO and Managing Director of Opthea, where the company's lead asset was advanced through preclinical studies to global Phase 3 registrational trials. Dr Baldwin also has extensive capital raising experience, including the completion of an A\$180 million initial public offering (IPO) and listing on the US Nasdaq exchange. Prior to Opthea, Dr Baldwin was previously employed at Genentech (now Roche) as a researcher, before moving to Genentech's commercial division. Dr Baldwin's experience in oncology drug development includes both preclinical and clinical investigation of inhibitors targeting angiogenic factors involved in tumour growth and spread, as well as management of competitive intelligence activities to support Genentech's early-stage oncology programs. Dr Baldwin holds a PhD in Medicine from the University of Melbourne, having conducted her doctoral studies at the Ludwig Institute for Cancer Research.

### **Corporate**

During the six months ended 31 December 2024, 3,409,020 options were exercised, contributing \$1.022m in cash toward advancing additional preclinical programs to support Race's clinical advancement.

### **Financial performance**

The operating profit for the six months ended 31 December 2024 was \$502,163 or \$1,380,713 excluding share-based payments (a non-cash expense). As at 31 December 2024, the Company had \$18,781,885 in cash reserves (compared with \$17,188,827 at 30 June 2024).

### **Principal activities**

#### **Preclinical Activities**

On 4 October 2024, Race submitted a provisional patent application for the RC220 bisantrene formulation. This patent, if granted, would provide exclusive IP protection for the RC220 formulation until October 2044.

On 21 November 2024, Race announced the discovery of 39 unique FTO protein-binding molecules identified using state-of-the-art NMR fragment screening. The identified compounds are confirmed FTO-binding chemical structures for the development of novel FTO targeting drugs and provide valuable new IP, aiding the development of novel m<sup>6</sup>A RNA epigenetic pathway drugs. This FTO-targeted drug discovery program was completed in collaboration with the Monash University Fragment Platform (MFP).

## **Clinical Activities**

On 30 July 2024, Race announced that the investigator-sponsored Phase 1b/2 trial of bisantrene in combination with clofarabine and fludarabine (Bis/Clo/Flu) in relapsed or refractory acute myeloid leukaemia (R/R AML) patients had been successfully concluded, having achieved its primary endpoint for efficacy. The trial (NCT04989335) was conducted at the Chaim Sheba Medical Centre in Israel under the supervision of AML key opinion leader Professor Arnon Nagler. As previously disclosed (ASX Announcement: 6 November 2023), six of the 15 evaluable patients (40%) in the Phase 2 efficacy stage responded to the Bis/Clo/Flu treatment (five complete responses, one partial response), with three of the clinical responders having active extramedullary disease. Five of the six treatment-responsive patients were able to be bridged to a potentially curative stem cell transplant within one to three months of treatment.

Race made significant progress in advancing the Phase 1a/b clinical trial of RC220 bisantrene in solid tumour patients with all paperwork required for submission of the human ethics application completed, including the Investigator Brochure, Clinical Protocol, Pharmacy Manual, Laboratory Manual, and Patient Informed Consent Forms.

## **Matters subsequent to the end of the financial half-year**

Dr Megan Baldwin was appointed as a Non-Executive Director on 1 January 2025.

Subsequent to 31 December 2024, the Company issued 9,135 fully paid ordinary shares at an issue price of \$1.25 per share following the exercise of 9,135 options.

Following the initial ethics submission to HREC, Race received a request for minor clarifications on some aspects of the trial protocol and associated documentation in late December 2024. No fundamental issues with the design or safety of the study were raised by the committee. Such clarification requests are common and expected upon first HREC submission. All HREC questions have been addressed by the Race team, and the associated ethics and regulatory data package was updated with the requested clarifications in mid-January 2025. Subject to final ethics and governance approvals, site activation and first patient recruitment is expected in Q1 CY2025.

Except for the above, no other matters or circumstances have arisen since 31 December 2024 that have significantly affected or could significantly affect the operations of the Company, the results of those operations, or the state of affairs of the Company in future financial years.

## **Auditor's Independence Declaration under Section 307C of the Corporations Act 2001**

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this Directors' report.

This report is made in accordance with a resolution of Directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the Directors

*Daniel Tillett*

---

Daniel Tillett  
Managing Director

25 February 2025

Type text here

To the Board of Directors,

**AUDITOR'S INDEPENDENCE DECLARATION UNDER SECTION 307C OF THE CORPORATIONS ACT 2001**

As lead audit director for the review of the financial statements of Race Oncology Limited and the entities it controlled for the half year ended 31 December 2024, I declare that to the best of my knowledge and belief, there have been no contraventions of:

- the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- any applicable code of professional conduct in relation to the review.

Yours Faithfully,



**HALL CHADWICK WA AUDIT PTY LTD**



**D M BELL FCA  
Director**

Dated this 25<sup>th</sup> day of February 2025  
Perth, Western Australia

**Race Oncology Limited**  
**Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income**  
**For the half-year ended 31 December 2024**

		<b>Consolidated</b>	
	<b>Note</b>	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
		<b>\$</b>	<b>\$</b>
<b>Revenue</b>			
Other income	2	5,254,557	4,003,470
Interest received		363,010	461,428
<b>Expenses</b>			
Administrative expenses		(4,577)	(17,027)
Accounting and audit fees		(151,600)	(67,313)
Depreciation and amortisation expense	3	(140,598)	(140,598)
Business development and marketing		(125,699)	(305,501)
R&D manufacturing and distribution		(379,673)	(1,844,129)
Corporate advice expense		(139,721)	(173,605)
Directors' fees		(59,646)	(195,158)
Employee benefits expense		(295,008)	(428,015)
Research and development expenses		(2,441,481)	(6,104,810)
Share based payment expenses		(878,550)	(284,314)
Share registry		(48,996)	(52,912)
Other expenses		(449,855)	(514,674)
<b>Profit/(loss) before income tax expense</b>		<b>502,163</b>	<b>(5,663,158)</b>
Income tax expense		-	-
<b>Profit/(loss) after income tax expense for the half-year attributable to the owners of Race Oncology Limited</b>		<b>502,163</b>	<b>(5,663,158)</b>
<b>Other comprehensive income</b>			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Foreign currency translation		595	3,797
Other comprehensive income for the half-year, net of tax		595	3,797
<b>Total comprehensive income for the half-year attributable to the owners of Race Oncology Limited</b>		<b>502,758</b>	<b>(5,659,361)</b>
		<b>Cents</b>	<b>Cents</b>
Basic earnings per share		0.29	(3.46)
Diluted earnings per share		0.26	(3.46)

*The above condensed consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes*

**Race Oncology Limited**  
**Condensed Consolidated Statement of Financial Position**  
**As at 31 December 2024**

		<b>Consolidated</b>	
	<b>Note</b>	<b>31 Dec 2024</b>	<b>30 Jun 2024</b>
		<b>\$</b>	<b>\$</b>
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents		18,781,885	17,188,827
Trade and other receivables		40,365	105,693
Other		178,569	122,094
<b>Total current assets</b>		<u>19,000,819</u>	<u>17,416,614</u>
<b>Non-current assets</b>			
Intangible Assets	3	<u>2,671,361</u>	<u>2,811,959</u>
<b>Total non-current assets</b>		<u>2,671,361</u>	<u>2,811,959</u>
<b>Total assets</b>		<u>21,672,180</u>	<u>20,228,573</u>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables	4	804,992	1,753,244
Provisions		118,023	114,925
<b>Total current liabilities</b>		<u>923,015</u>	<u>1,868,169</u>
<b>Non-current liabilities</b>			
Provisions		33,890	48,256
<b>Total non-current liabilities</b>		<u>33,890</u>	<u>48,256</u>
<b>Total liabilities</b>		<u>956,905</u>	<u>1,916,425</u>
<b>Net assets</b>		<u>20,715,275</u>	<u>18,312,148</u>
<b>Equity</b>			
Issued and Unissued Capital	5	68,450,924	66,947,929
Reserves	6	9,180,346	8,782,377
Accumulated losses		(56,915,995)	(57,418,158)
<b>Total equity</b>		<u>20,715,275</u>	<u>18,312,148</u>

*The above condensed consolidated statement of financial position should be read in conjunction with the accompanying notes*

**Race Oncology Limited**  
**Condensed Consolidated Statement of Changes in Equity**  
**For the half-year ended 31 December 2024**

<b>Consolidated</b>	<b>Issued capital</b> <b>\$</b>	<b>Reserves</b> <b>\$</b>	<b>Retained profits</b> <b>\$</b>	<b>Total equity</b> <b>\$</b>
Balance at 1 July 2023	61,709,155	7,375,808	(43,598,822)	25,486,141
Loss after income tax expense for the half-year	-	-	(5,663,158)	(5,663,158)
Other comprehensive income for the half-year, net of tax	-	3,797	-	3,797
Total comprehensive income for the half-year	-	3,797	(5,663,158)	(5,659,361)
<i>Transactions with owners in their capacity as owners:</i>				
Shares issued on exercise of options	320,603	-	-	320,603
Share-based payments (note 7)	-	589,928	-	589,928
Lapse of options	-	(305,614)	-	(305,614)
Balance at 31 December 2023	<u>62,029,758</u>	<u>7,663,919</u>	<u>(49,261,980)</u>	<u>20,431,697</u>
<b>Consolidated</b>	<b>Issued capital</b> <b>\$</b>	<b>Reserves</b> <b>\$</b>	<b>Retained profits</b> <b>\$</b>	<b>Total equity</b> <b>\$</b>
Balance at 1 July 2024	66,947,929	8,782,377	(57,418,158)	18,312,148
Profit after income tax expense for the half-year	-	-	502,163	502,163
Other comprehensive income for the half-year, net of tax	-	595	-	595
Total comprehensive income for the half-year	-	595	502,163	502,758
<i>Transactions with owners in their capacity as owners:</i>				
Share-based payments (note 7)	-	1,039,708	-	1,039,708
Lapse of options	-	(161,158)	-	(161,158)
Shares issued on exercise of options	1,502,995	(481,176)	-	1,021,819
Balance at 31 December 2024	<u>68,450,924</u>	<u>9,180,346</u>	<u>(56,915,995)</u>	<u>20,715,275</u>

*The above condensed consolidated statement of changes in equity should be read in conjunction with the accompanying notes*

**Race Oncology Limited**  
**Condensed Consolidated Statement of Cash Flows**  
**For the half-year ended 31 December 2024**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
<b>Cash flows from operating activities</b>		
Government grants	5,254,557	1,657,956
Payments for research and development	(3,036,440)	(6,465,193)
Payments for business development and marketing	(147,457)	(289,830)
Payments for manufacturing and distribution	(387,211)	(1,856,942)
Payments to suppliers and employees	<u>(1,475,815)</u>	<u>(1,662,024)</u>
	207,634	(8,616,033)
Interest received	<u>363,010</u>	<u>461,428</u>
Net cash from/(used in) operating activities	<u>570,644</u>	<u>(8,154,605)</u>
<b>Cash flows from investing activities</b>		
Net cash from investing activities	<u>-</u>	<u>-</u>
<b>Cash flows from financing activities</b>		
Proceeds from issue of shares	<u>1,021,819</u>	<u>320,603</u>
Net cash from financing activities	<u>1,021,819</u>	<u>320,603</u>
Net increase/(decrease) in cash and cash equivalents	1,592,463	(7,834,002)
Cash and cash equivalents at the beginning of the financial half-year	17,188,827	21,520,368
Effects of exchange rate changes on cash and cash equivalents	<u>595</u>	<u>29,081</u>
Cash and cash equivalents at the end of the financial half-year	<u><u>18,781,885</u></u>	<u><u>13,715,447</u></u>

*The above condensed consolidated statement of cash flows should be read in conjunction with the accompanying notes*

**Race Oncology Limited**  
**Notes to the Condensed Consolidated Financial Statements**  
**For the half-year ended 31 December 2024**

**Note 1. Material accounting policy information**

These general purpose financial statements for the interim half-year reporting period ended 31 December 2024 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2024 and any public announcements made by the company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

**New or amended Accounting Standards and Interpretations adopted**

The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

**Segment information**

**Identification of reportable segments**

The consolidated entity has identified its operating segments based on the internal reports that are reviewed and used by the Board of Directors (the chief operating decision makers) in assessing performance and in determining the allocation of resources.

During the half-year period, the consolidated entity is operated in two segments, being research into oncology drug, bisantrene, and the manufacturing and distribution of the drug for clinical trials. Accordingly, the financial information reported elsewhere in this financial report is representative of the nature and financial effects of the business activities in which it engages and the economic environment in which it operates.

**Note 2. Other income**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
Research and development tax incentive	<u>5,254,557</u>	<u>4,003,470</u>

**Note 3. Non-current assets - Intangible Assets**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>30 Jun 2024</b>
	<b>\$</b>	<b>\$</b>
Intellectual property	5,000,000	5,000,000
Less: Accumulated amortisation	<u>(2,328,639)</u>	<u>(2,188,041)</u>
	<u>2,671,361</u>	<u>2,811,959</u>

**Consolidated**

	Intellectual Property
	\$
Balance at 1 July 2024	2,811,959
Amortisation expense	<u>(140,598)</u>
Balance at 31 December 2024	<u>2,671,361</u>

**Race Oncology Limited**  
**Notes to the Condensed Consolidated Financial Statements**  
**For the half-year ended 31 December 2024**

**Note 3. Non-current assets - Intangible Assets (continued)**

Intellectual property totalling \$5,000,000 comprises patents and licenses initially acquired by the Company and pertain to the oncology drug, called bisantrene. The initial acquisition of intellectual property was supported by 2 patent applications. Subsequent to the initial patent applications the Company strategy has evolved to include a total of six patent families. The portfolio of patents is a robust program and the two most recent patent applications expand bisantrene's protected use of combination therapies. The patents' useful life has been aligned to the patent term and as a result, those patents are amortised on a straight-line basis over the period of the patent. The amortisation expense has been included in the line item 'amortisation' in profit or loss.

The Directors do not consider there have been any indicators of impairment of the acquired intangible assets during the half year up until the date of this report.

**Note 4. Current liabilities - trade and other payables**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>30 Jun 2024</b>
	<b>\$</b>	<b>\$</b>
Trade and Other payables	485,161	1,199,041
Accruals	319,831	554,203
	<u>804,992</u>	<u>1,753,244</u>

Refer to note 9 for further information on financial instruments.

**Note 5. Equity - Issued and Unissued Capital**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>30 Jun 2024</b>
	<b>\$</b>	<b>\$</b>
Opening balance	66,947,929	61,709,155
Exercise of options	1,021,819	5,243,395
Transfer from option reserve	481,176	-
Less: capital raising costs	-	(4,621)
Closing Balance	<u>68,450,924</u>	<u>66,947,929</u>

The Company has issued share capital amounting to 173,712,723 (30 June 2024:170,303,703) ordinary shares of no par value and the Company does not have a limited amount of authorised capital.

**(a) Ordinary shares**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>30 Jun 2024</b>
	<b>No</b>	<b>No</b>
At the beginning of the reporting period	170,303,703	163,068,780
Shares issued during the year	<u>3,409,020</u>	<u>7,234,923</u>
At the end of the reporting period	<u>173,712,723</u>	<u>170,303,703</u>

*Share buy-back*

There is no current on-market share buy-back.

**Race Oncology Limited**  
**Notes to the Condensed Consolidated Financial Statements**  
**For the half-year ended 31 December 2024**

**Note 6. Equity - Reserves**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>30 Jun 2024</b>
	<b>\$</b>	<b>\$</b>
Foreign currency reserve	595	5,446
Share-based payments reserve	<u>9,179,751</u>	<u>8,776,931</u>
	<u><u>9,180,346</u></u>	<u><u>8,782,377</u></u>

**Note 7. Share-based payments**

The following share-based payment arrangements existed during the period to 31 December 2024:

On 1 September 2024, 249,908 Options issued to Mary Harney lapsed due to her cessation as a director.

On 1 November 2024, the Company issued the following incentives options to employees:

- a) 235,918 Options exercisable at \$2.11 and expiring on 30 June 2028 to an employee;
- b) 213,626 Options exercisable at \$2.11 and expiring on 30 June 2028 to an employee;
- c) 487,439 Options exercisable at \$2.11 and expiring on 30 June 2028 to an employee;
- d) 172,056 Options exercisable at \$2.11 and expiring on 30 June 2028 to an employee;
- e) 142,699 Options exercisable at \$2.11 and expiring on 30 June 2028 to an employee;

The vesting conditions for the incentive options are as follows:

- (i) 100% of Options will vest and become exercisable on 30 June 2025.

On 26 November 2024, the Company issued the following incentives options:

- a) 58,446 Options exercisable at \$2.04 and expiring on 25 November 2028 to Serge Scrofani;

The vesting conditions for the incentive options are as follows:

- (i) 100% of Options will vest and become exercisable into Shares on the date which is 12 months from the date of issue of the Options.

A summary of the Company options issued during the 6-months period is as follows:

<b>Recipient</b>	<b>Class of SBP</b>	<b>Quantity</b>	<b>Share price at Grant date \$</b>	<b>Value recognised during the year \$</b>	<b>Value to be recognised in future years \$</b>
Employee	Unlisted Options	235,918	\$1.48	33,332	100,552
Employee	Unlisted Options	213,626	\$1.48	30,183	91,050
Employee	Unlisted Options	487,439	\$1.48	68,869	207,753
Employee	Unlisted Options	172,056	\$1.48	24,309	73,333
Employee	Unlisted Options	142,699	\$1.48	20,161	60,820
Sergio Scrofani	Unlisted Options	<u>58,446</u>	\$1.43	<u>3,356</u>	<u>31,644</u>
		<u><u>1,310,184</u></u>		<u><u>180,210</u></u>	<u><u>565,152</u></u>

**Race Oncology Limited**  
**Notes to the Condensed Consolidated Financial Statements**  
**For the half-year ended 31 December 2024**

**Note 7. Share-based payments (continued)**

For the options granted during the current financial half-year, the valuation model inputs used to determine the fair value at the grant date, are as follows:

Employees

Grant date	Expiry date	Share price at grant date \$	Exercise price \$	Expected volatility %	Risk-free interest rate %	Quantity	Total value at grant date \$
01/11/2024	30/06/2028	\$1.48	\$2.11	61.30%	4.01%	235,918	133,883
01/11/2024	30/06/2028	\$1.48	\$2.11	61.30%	4.01%	213,626	121,233
01/11/2024	30/06/2028	\$1.48	\$2.11	61.30%	4.01%	487,439	276,622
01/11/2024	30/06/2028	\$1.48	\$2.11	61.30%	4.01%	172,056	97,642
01/11/2024	30/06/2028	\$1.48	\$2.11	61.30%	4.01%	142,699	80,981

Sergio Scrofani

Grant date	Expiry date	Share price at grant date \$	Exercise Price \$	Expected volatility %	Risk-free interest rate %	Quantity	Total value at grant date \$
26/11/2024	25/11/2028	\$1.43	\$2.05	62.80%	4.12%	58,446	35,000

**Note 8. Contingent liabilities**

As of the date of this report, there are no claims or contingent liabilities that are expected to materially affect the company's financial position or results of operations, either individually or in the aggregate.

**Note 9. Financial instruments**

The Company's financial instruments consist of trade and other receivables, deposits paid, trade and other payables, and financial liabilities. These financial instruments are measured at amortised cost, less any provision for non-recovery. The carrying amounts of the financial assets and liabilities approximate their fair value.

**Note 10. Events after the reporting period**

Dr Megan Baldwin was appointed as a Non-Executive Director on 1 January 2025.

Subsequent to 31 December 2024, the company issued 9,135 Fully paid ordinary shares at an issue price of \$1.25 per share following the exercise of 9,135 options.

Following the initial submission to HREC, Race received a request for minor clarifications on some aspects of the trial protocol and associated documentation in late December 2024. No fundamental issues with the design or safety of the study were raised by the committee. Such clarification requests are common and expected on first HREC submission. All HREC questions have been addressed by the Race team, and the associated ethics and regulatory data package was updated with the requested clarifications in mid-January 2025. Subject to final ethics approval and governance approval, site activation and first patient recruitment is expected in Q1 CY2025.

Except for the above, no other matters or circumstances have arisen since 31 December 2024 that have significantly affected or could significantly affect the operations of the Company, the results of those operations, or the state of affairs of the Company in future financial years.

**Note 11. Related party transactions**

The related party transactions of the half-year financial report are consistent with those adopted and disclosed in the Company's 2024 annual financial report for the financial year ended 30 June 2024.

**Race Oncology Limited**  
**Directors' Declaration**  
**For the half-year ended 31 December 2024**

The Directors of the Company declare that:

- the condensed financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001, and other mandatory professional reporting requirements;
- the condensed financial statements and notes give a true and fair view of the consolidated entity's financial position as at 31 December 2024 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the Directors

*Daniel Tillett*

---

Daniel Tillett  
Managing Director

25 February 2025

## INDEPENDENT AUDITOR'S REVIEW REPORT TO THE MEMBERS OF RACE ONCOLOGY LIMITED

### Conclusion

We have reviewed the accompanying half-year financial report of Race Oncology Limited ("the Company") and Controlled Entities ("the Consolidated Entity") which comprises the condensed consolidated statement of financial position as at 31 December 2024, the condensed consolidated statement of profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the half-year ended on that date, a summary of material accounting policies and other selected explanatory notes, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Race Oncology Limited and Controlled Entities does not comply with the *Corporations Act 2001* including:

- a. Giving a true and fair view of the Consolidated Entity's financial position as at 31 December 2024 and of its performance for the half-year ended on that date; and
- b. Complying with Accounting Standard AASB 134: *Interim Financial Reporting* and *Corporations Regulations 2001*.

### Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001* which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's review report.

### Responsibility of the Directors for the Financial Report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

### Auditor's Responsibility for the Review of the Financial Report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Consolidated Entity's financial position as at 31 December 2024 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all material matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



**HALL CHADWICK WA AUDIT PTY LTD**



**D M BELL FCA**  
**Director**

Dated this 25<sup>th</sup> day of February 2025  
Perth, Western Australia

For personal use only



[www.raceoncology.com](http://www.raceoncology.com)